MX9702154A - Compuestos, intermediarios, procesos, composiciones y metodos de naftilo. - Google Patents
Compuestos, intermediarios, procesos, composiciones y metodos de naftilo.Info
- Publication number
- MX9702154A MX9702154A MX9702154A MX9702154A MX9702154A MX 9702154 A MX9702154 A MX 9702154A MX 9702154 A MX9702154 A MX 9702154A MX 9702154 A MX9702154 A MX 9702154A MX 9702154 A MX9702154 A MX 9702154A
- Authority
- MX
- Mexico
- Prior art keywords
- processes
- intermediates
- compositions
- methods
- compounds
- Prior art date
Links
- 125000001624 naphthyl group Chemical group 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- -1 processes Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010027304 Menopausal symptoms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 abstract 1
- 201000007954 uterine fibroid Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Electroluminescent Light Sources (AREA)
- Plural Heterocyclic Compounds (AREA)
- Silicon Polymers (AREA)
Abstract
La presente invencion proporciona ciertos compuestos de naftilo y dihidro novedosos, los cuales son utiles para aliviar los síntomas del síndrome postmenopáusico, incluyendo la osteoporosis, hiperlipidemia y cáncer dependiente de estrogenos, e inhibicion de la enfermedad fibroide uterina, endometriosis, y proliferacion celular del musculo liso aortal. También proporciona los procesos para preparar tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/309,525 US7501441B1 (en) | 1994-09-20 | 1994-09-20 | Naphthyl compounds, intermediates, processes, compositions, and methods |
PCT/US1995/012346 WO1996009039A1 (en) | 1994-09-20 | 1995-09-18 | Naphthyl compounds, intermediates, processes, compositions, and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9702154A true MX9702154A (es) | 1997-06-28 |
Family
ID=23198583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702154A MX9702154A (es) | 1994-09-20 | 1995-09-18 | Compuestos, intermediarios, procesos, composiciones y metodos de naftilo. |
Country Status (29)
Country | Link |
---|---|
US (6) | US7501441B1 (es) |
EP (1) | EP0703228B1 (es) |
JP (1) | JPH10506392A (es) |
KR (1) | KR970705983A (es) |
AT (1) | ATE214058T1 (es) |
AU (1) | AU697114B2 (es) |
BR (1) | BR9508967A (es) |
CA (1) | CA2200449A1 (es) |
CO (1) | CO4410318A1 (es) |
CZ (1) | CZ291207B6 (es) |
DE (1) | DE69525699T2 (es) |
DK (1) | DK0703228T3 (es) |
ES (1) | ES2173154T3 (es) |
HU (1) | HUT77919A (es) |
IL (1) | IL115335A (es) |
MX (1) | MX9702154A (es) |
MY (1) | MY132075A (es) |
NO (1) | NO307929B1 (es) |
NZ (1) | NZ294177A (es) |
PE (1) | PE47496A1 (es) |
PL (1) | PL319454A1 (es) |
PT (1) | PT703228E (es) |
RU (1) | RU2165924C2 (es) |
SI (1) | SI0703228T1 (es) |
TR (1) | TR199501135A2 (es) |
TW (1) | TW399036B (es) |
WO (1) | WO1996009039A1 (es) |
YU (1) | YU61595A (es) |
ZA (1) | ZA957857B (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994026303A1 (en) | 1993-05-13 | 1994-11-24 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US6451817B1 (en) * | 1995-03-10 | 2002-09-17 | Eli Lilly And Company | Alpha-substituted-1-benzyl-napthyls |
US6391892B1 (en) * | 1995-03-10 | 2002-05-21 | Eli Lilly And Company | Naphthyl pharmaceutical compounds |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
ATE377418T1 (de) | 1995-06-07 | 2007-11-15 | Poniard Pharmaceuticals Inc | Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen |
US5811421A (en) * | 1995-07-31 | 1998-09-22 | Eli Lilly And Company | Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods |
GB2312844A (en) * | 1996-05-07 | 1997-11-12 | Lilly Co Eli | A naphthyl compound for the treatment of immune-complex diseases |
CA2213814A1 (en) * | 1996-08-29 | 1998-02-28 | Henry Uhlman Bryant | Naphthalene compounds, intermediates, formulations, and methods |
US6599920B2 (en) * | 1996-08-29 | 2003-07-29 | Eli Lilly And Company | Naphthalene compounds, intermediates, formulations, and methods |
ID19392A (id) | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
CA2214070C (en) * | 1996-08-29 | 2006-03-14 | Eli Lilly And Company | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods |
SI0826679T1 (en) * | 1996-08-29 | 2002-04-30 | Eli Lilly And Company | Naphthyl compounds and compositions |
CA2214929A1 (en) * | 1996-09-26 | 1998-03-26 | Charles Willis Lugar, Iii | Naphthofluorene compounds, intermediates, compositions and methods |
CA2214196A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods |
CA2214931A1 (en) * | 1996-09-26 | 1998-03-26 | Henry Uhlman Bryant | Tetrahydrobenzo-a-fluorene compounds and method of use |
CA2215856A1 (en) * | 1996-09-26 | 1998-03-26 | Eli Lilly And Company | Dihydrobenzofluorene compounds, intermediates, compositions, and methods |
US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
CA2216592C (en) * | 1996-10-24 | 2006-07-18 | Brian Stephen Muehl | Benzothiophene compounds, intermediates, compositions, and methods |
CA2215647A1 (en) * | 1996-10-24 | 1998-04-24 | Eli Lilly And Company | Naphthyl compounds, compositions, and methods |
CA2214872C (en) * | 1996-10-24 | 2002-01-22 | Eli Lilly And Company | Benzothiophene compounds, compositions and methods |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
IT1298159B1 (it) * | 1997-01-28 | 1999-12-20 | Hoffmann La Roche | Derivati di un 5-aroilnaftalene |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
CA2287244A1 (en) * | 1997-04-25 | 1998-11-05 | Henry Uhlman Bryant | Indene compounds having activity as serms |
ES2239793T3 (es) | 1997-08-07 | 2005-10-01 | Eli Lilly And Company | Compuestos de 1-(4-(alcoxi sustituido)bencil)naftaleno con actividad inhibidora de estrogenos. |
US6107346A (en) * | 1997-08-11 | 2000-08-22 | Eli Lilly And Company | Methods for treating hyperlipidemia |
US6090843A (en) * | 1997-08-11 | 2000-07-18 | Eli Lilly And Company | Benzothiophenes compounds which have useful pharmaceutical activity |
US5929090A (en) * | 1997-09-12 | 1999-07-27 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods |
US5834488A (en) * | 1997-09-19 | 1998-11-10 | Eli Lilly And Company | Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods |
CA2306489A1 (en) | 1997-10-03 | 1999-04-15 | Mark Gregory Stocksdale | Benzothiophenes |
US6060488A (en) * | 1998-09-22 | 2000-05-09 | Eli Lilly And Company | Benzothiophenes for treating estrogen deficiency |
DK1175433T3 (da) | 1999-05-04 | 2005-09-19 | Strakan Int Ltd | Androgenglycosider og androgen aktivitet deraf |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
DE60210283T2 (de) | 2001-05-22 | 2006-11-09 | Eli Lilly And Co., Indianapolis | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
CA2444787A1 (en) | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
JP4656939B2 (ja) * | 2002-07-22 | 2011-03-23 | イーライ リリー アンド カンパニー | フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター |
EA007978B1 (ru) * | 2003-02-25 | 2007-02-27 | Эли Лилли Энд Компани | Кристаллический несольватированный гидрохлорид 1-(4-(2-пиперидинилэтокси)фенокси)-2-(4-метансульфонилфенил)-6-гидроксинафталина |
US20060167051A1 (en) * | 2003-02-25 | 2006-07-27 | Remick David M | Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
CA2512663A1 (en) | 2003-02-25 | 2004-09-10 | Eli Lilly And Company | Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
EP1692101B1 (en) * | 2003-03-31 | 2011-07-06 | Council of Scientific and Industrial Research | Mercapto-phenyl-naphthyl-methane derivatives and preparation thereof |
CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
US20070191319A1 (en) * | 2003-12-17 | 2007-08-16 | Pfizer Inc. | Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen |
EP1709023B1 (en) | 2004-01-22 | 2009-11-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
EP1709022A1 (en) * | 2004-01-22 | 2006-10-11 | Eli Lilly And Company | Selective estrogen receptor modulators |
US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
JP2007528408A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス, インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
KR20070084455A (ko) * | 2004-11-23 | 2007-08-24 | 워너-램버트 캄파니 엘엘씨 | 지질혈증 치료용 hmg co-a 환원효소 억제제로서의7-(2h-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체 |
CA2599611C (en) * | 2005-02-09 | 2013-07-30 | Chiang J. Li | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
US7655700B2 (en) | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
ES2382009T3 (es) | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares |
WO2010036497A2 (en) * | 2008-09-29 | 2010-04-01 | Eli Lilly And Company | Selective estrogen receptor modulator |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
CA2802761C (en) | 2010-06-16 | 2017-01-03 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
CA3090807A1 (en) | 2018-02-21 | 2019-08-29 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3396169A (en) | 1966-10-26 | 1968-08-06 | Upjohn Co | Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes |
US3274213A (en) | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
FR90418E (fr) * | 1962-09-13 | 1967-12-08 | Ici Ltd | Nouveaux dérivés alkéniques |
US3862232A (en) | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3313853A (en) | 1963-10-16 | 1967-04-11 | Upjohn Co | 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones |
US3293263A (en) | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3522319A (en) * | 1964-01-23 | 1970-07-28 | Ciba Geigy Corp | Phenol substituted tetrahydronaphthalenes useful as estrogenics |
US3320271A (en) | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
GB1138163A (en) | 1965-05-21 | 1968-12-27 | Bristol Myers Co | Benzothiophene derivatives having anti-fertility properties |
US3394125A (en) | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
US3483293A (en) | 1967-12-15 | 1969-12-09 | Upjohn Co | Method for controlling birds and rodents |
US3567737A (en) | 1968-01-02 | 1971-03-02 | Upjohn Co | Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes |
IL45454A (en) * | 1973-08-31 | 1977-06-30 | Ciba Geigy Ag | 3-methyl-4-(p-phenoxy(or benzyl)-phenoxy)-2-butene derivatives their preparation and pest-population contaol compositions containing them |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4230862A (en) | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
EP0062503A1 (en) * | 1981-04-03 | 1982-10-13 | Eli Lilly And Company | Benzothiophene compounds and process for preparing them |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
DE3121175A1 (de) * | 1981-05-27 | 1982-12-16 | Klinge Pharma GmbH, 8000 München | Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
GB8311678D0 (en) | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
FR2599031B1 (fr) * | 1986-05-23 | 1988-07-22 | Oreal | Nouveaux composes naphtyl aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique |
US4859695A (en) * | 1986-06-10 | 1989-08-22 | Merck & Co., Inc. | Antiestrogen agents having anabolic activity in animals |
US4851554A (en) * | 1987-04-06 | 1989-07-25 | University Of Tennessee Research Corporation | Certain 3-substituted 2-alkyl benzofuran derivatives |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5254568A (en) | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
DE4122484A1 (de) | 1991-07-06 | 1993-01-07 | Teves Gmbh Alfred | Schaltungsanordnung zur erkennung von radsensordefekten |
US5147880A (en) * | 1991-07-22 | 1992-09-15 | Eli Lilly And Company | Benzo[a]fluorene compounds |
JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
US5384332A (en) * | 1994-05-11 | 1995-01-24 | Eli Lilly And Company | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
-
1994
- 1994-09-20 US US08/309,525 patent/US7501441B1/en not_active Expired - Fee Related
-
1995
- 1995-04-21 US US08/428,924 patent/US5484797A/en not_active Expired - Fee Related
- 1995-04-21 US US08/426,542 patent/US5484795A/en not_active Expired - Fee Related
- 1995-04-21 US US08/426,318 patent/US6437137B1/en not_active Expired - Fee Related
- 1995-04-21 US US08/428,922 patent/US6410564B1/en not_active Expired - Fee Related
- 1995-04-21 US US08/426,770 patent/US5484796A/en not_active Expired - Fee Related
- 1995-09-18 CA CA002200449A patent/CA2200449A1/en not_active Abandoned
- 1995-09-18 MY MYPI95002757A patent/MY132075A/en unknown
- 1995-09-18 CO CO95042772A patent/CO4410318A1/es unknown
- 1995-09-18 ES ES95306549T patent/ES2173154T3/es not_active Expired - Lifetime
- 1995-09-18 SI SI9530587T patent/SI0703228T1/xx unknown
- 1995-09-18 PE PE1995279259A patent/PE47496A1/es not_active Application Discontinuation
- 1995-09-18 DK DK95306549T patent/DK0703228T3/da active
- 1995-09-18 IL IL11533595A patent/IL115335A/xx active IP Right Grant
- 1995-09-18 TW TW084109782A patent/TW399036B/zh not_active IP Right Cessation
- 1995-09-18 NZ NZ294177A patent/NZ294177A/xx unknown
- 1995-09-18 RU RU97106345/04A patent/RU2165924C2/ru active
- 1995-09-18 PL PL95319454A patent/PL319454A1/xx unknown
- 1995-09-18 CZ CZ1997822A patent/CZ291207B6/cs not_active IP Right Cessation
- 1995-09-18 HU HU9801473A patent/HUT77919A/hu unknown
- 1995-09-18 KR KR1019970701827A patent/KR970705983A/ko active IP Right Grant
- 1995-09-18 EP EP95306549A patent/EP0703228B1/en not_active Expired - Lifetime
- 1995-09-18 ZA ZA957857A patent/ZA957857B/xx unknown
- 1995-09-18 BR BR9508967A patent/BR9508967A/pt not_active Application Discontinuation
- 1995-09-18 DE DE69525699T patent/DE69525699T2/de not_active Expired - Fee Related
- 1995-09-18 AU AU36863/95A patent/AU697114B2/en not_active Ceased
- 1995-09-18 PT PT95306549T patent/PT703228E/pt unknown
- 1995-09-18 JP JP8511132A patent/JPH10506392A/ja not_active Withdrawn
- 1995-09-18 MX MX9702154A patent/MX9702154A/es not_active IP Right Cessation
- 1995-09-18 AT AT95306549T patent/ATE214058T1/de not_active IP Right Cessation
- 1995-09-18 WO PCT/US1995/012346 patent/WO1996009039A1/en active IP Right Grant
- 1995-09-19 TR TR95/01135A patent/TR199501135A2/xx unknown
- 1995-09-19 YU YU61595A patent/YU61595A/sh unknown
-
1997
- 1997-03-19 NO NO971278A patent/NO307929B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9702154A (es) | Compuestos, intermediarios, procesos, composiciones y metodos de naftilo. | |
NZ323456A (en) | Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis | |
IL129851A0 (en) | Purification of neurotrophins | |
MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
DE69629624D1 (de) | Verbindungen mit stickstoffenthaltenden nichtbasischen Seitenketten und diese enthaltende Zubereitungen | |
YU35802A (sh) | Polimorfni oblik atorvastatin kalcijuma | |
IL139956A0 (en) | Conformationally constrained backbone cyclized somatostatin analogs | |
ZA992877B (en) | Process for the preparation of hyndrocarbons from synthesis gas. | |
MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
CA2209925A1 (en) | 5,6-diaryl-5,6,7,8-tetrahydronaphthalenes and their analogs as estrogen agonists/antagonists | |
AU2586895A (en) | Compounds for inhibiting osteoclast-mediated bone resorption | |
ZA994059B (en) | Process for the preparation of hydrocarbon from synthesis gas. | |
ZA200108083B (en) | Compositions for improving fertility. | |
BG103548A (en) | Vitronectine receptor antagonists | |
AP9801269A0 (en) | Prostaglandin agonists. | |
PL342999A1 (en) | Glucocorticoid-selective antiinflammatory agents | |
MXPA03001463A (es) | Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen. | |
MY122278A (en) | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | |
WO1997029739A3 (en) | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
MY120426A (en) | Use of amines to produce drugs for preventing tumour cell proliferation | |
MY133390A (en) | Azabicyclic 5ht1 receptor ligands | |
DE69635852D1 (de) | Verbindungen mit Stickstoff enthaltenden, nichtbasischen Seitenketten und diese enthaltende Zubereitungen | |
AP1402A (en) | Prevention of migraine recurrence. | |
WO2002020000A3 (en) | Combined estrogen blockade of the breast with exemestane and raloxifene | |
BG102229A (en) | Endothelium receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |